uniQure N.V. (QURE) - Episode 66 - Sep 25, 2025

Biotech company uniQure (QURE) just delivered a market bombshell, soaring 248% in a single session after announcing a game-changing breakthrough for its Huntington's disease drug. The explosive move ignited a brutal short squeeze, incinerating bearish bets and forcing a complete re-evaluation of the company's future. But after such a historic, vertical run-up, is the stock now dangerously overbought and due for a sharp pullback, or is this just the first stage of a much larger rally? In this episode, we dissect the seismic shift in fundamentals, analyze the battleground sentiment between bulls and squeezed bears, and identify the critical technical levels that will define where QURE goes from here.

There are no comments yet.

Please log in to write the first comment.